

Clinical Experience

Clinical experience across bleeding-related studies, including UGIB and cardiac surgery

- Reduced fibrinolytic activity
- Improved clot stability
- Reduced bleeding-related complications
- Lower blood product utilization
- Strong safety profile

Clinical Findings Across Studies

UGIB Study

- Fewer re-bleeding events observed
- Lower observed mortality (trend)
- No thromboembolic complications observed

Cardiac Study

- Fewer major bleeding events observed
- Fewer bleeding re-interventions observed
- Lower plasma unit utilization

Contact us for clinical collaboration, hospital implementation, or distribution opportunities.

www.plas-free.com
info@plas-free.com



QD-10-001 REV.02



ClearPlasma

Transforming Plasma Into a Hemostatic Tool




Selective plasminogen filtration supporting clot stability during active bleeding

For blood bank and bedside plasma transfusion workflows

Active Bleeding Requires Durable Hemostatic Control

- Plasma is the standard of care in bleeding management
- Fibrinolysis destabilizes clot formation
- Standard plasma contains plasminogen



ClearPlasma selectively removes plasminogen while preserving key coagulation factors

Product Information

Device Type	Single-use, gamma-sterilized plasma adsorber
Processing Capacity	Up to 250 mL plasma
Mechanism	Selective plasminogen adsorption
Plasminogen Reduction	≥90% depletion
Filtration Time	~30–60 min
Workflow Options	Blood Bank / Bedside
Sterilization	Gamma radiation
Storage Conditions	2–8°C
Shelf Life	24 months

Application Areas

Trauma

Emergency Surgery

Elective Surgeries

Active Life-Threatening Bleeding

Designed for Integration into Standard Bleeding Care

Blood Bank Use




Pre-transfusion plasma processing for later clinical use

Bedside Use



Real-time plasma filtration during transfusion



Same plasma workflow. No systemic drug exposure. Plasma optimized for hemostatic support

Compatible with plasma from all ABO blood groups